Pharmstandard

Pharmstandard is a Russian pharmaceutical company established in 2003 through a merger. The company develops, manufactures, and exports a broad portfolio of generic and proprietary medicines, serving prescription and over-the-counter segments. Its stated therapeutic coverage includes diabetes, growth hormone deficiency, cardiovascular disease, gastroenterology, neurology, infectious diseases, and oncology. The company has also been associated with Arbidol, an antiviral medicine that became one of its best-known commercial products. Pharmstandard operates a vertically organized manufacturing network in Russia. The facilities identified in reference material are located in Moscow, Ufa, Nizhny Novgorod, Kursk, Tomsk, and Tyumen. This geographic footprint gives the company production capacity across several Russian industrial and pharmaceutical centers and supports distribution within Russia as well as exports to other markets, particularly in the Commonwealth of Independent States. The company is described as manufacturing and exporting more than 400 generic and proprietary medicines, although the exact current product count and portfolio composition may change over time. The business was created during a period of consolidation in the Russian pharmaceutical sector. Its 2003 formation through a merger provided the corporate basis for later expansion and public-market activity. In May 2007, Pharmstandard completed an initial public offering that raised approximately US$880 million and valued the company at about US$2.2 billion. Roman Abramovich held a 17% stake until March 2008. These transactions placed the company among the more visible Russian pharmaceutical businesses in international capital markets. Pharmstandard later pursued expansion beyond finished medicines. In 2013 it announced plans to acquire Bever Pharmaceutical, an ingredient supplier. The announcement was followed by a reported 25% decline in Pharmstandard shares, indicating that investors viewed the proposed transaction as financially or strategically uncertain. The available reference material does not establish whether the acquisition was completed or provide detailed post-transaction results. The company was delisted from both the London and Moscow stock exchanges in 2017. Consequently, its historical public-company identity and the ticker PHST should be distinguished from its later private or non-exchange-traded status. Pharmstandard remains described as a Russian multinational pharmaceutical company, but publicly available reference material supplied for this entry does not provide enough information to identify current executives, ownership arrangements, recent financial performance, or the precise status of every product line. The brand's core identity is therefore best characterized as a Russia-based manufacturer and exporter of medicines, with a large therapeutic portfolio and a multi-site domestic production base.

Pharmstandard was established in 2003 through a merger, making its origin part of the consolidation of Russia's pharmaceutical manufacturing sector. From its formation, the company developed as a producer of both generic and proprietary medicines rather than as a single-product brand. Its portfolio has been described as covering more than 400 medicines and a wide range of therapeutic areas, including diabetes, growth hormone deficiency, cardiovascular conditions, gastrointestinal disorders, neurological diseases, infections, and cancer. The company expanded its manufacturing base through a network of six facilities in Russia. The sites identified in the available reference material are in Moscow, Ufa, Nizhny Novgorod, Kursk, Tomsk, and Tyumen. This network supports the production of medicines for the domestic Russian market and for export. Pharmstandard's operations have therefore combined pharmaceutical manufacturing with distribution and international sales, particularly in markets connected to Russia and the Commonwealth of Independent States. A major turning point came in May 2007, when Pharmstandard raised approximately US$880 million in an initial public offering. The offering valued the company at roughly US$2.2 billion and gave it a prominent position among publicly traded Russian pharmaceutical businesses. Roman Abramovich held a 17% stake in the company until March 2008. The available material does not identify the complete shareholder structure after that point, but the stake is a notable part of Pharmstandard's early public-market history. In 2013, Pharmstandard announced plans to acquire Bever Pharmaceutical, described as an ingredient supplier. The proposal indicated an interest in extending the company's position within the pharmaceutical supply chain rather than focusing solely on finished medicines. The announcement was followed by a reported 25% fall in Pharmstandard's shares. The supplied reference does not state whether the transaction ultimately closed, nor does it provide enough information to assess its operational consequences. Pharmstandard was delisted from the London and Moscow stock exchanges in 2017. This ended its exchange-listed phase and means that the historical ticker PHST should not be treated as evidence of current public trading. The company is nevertheless described in the reference material as a Russian multinational pharmaceutical business. Its best-known product association is Arbidol, while its broader identity rests on a large portfolio of prescription and non-prescription medicines manufactured at multiple Russian sites. The supplied sources do not establish a current executive roster, present ownership structure, recent revenues, current share status, or a definitive account of the company's post-delisting corporate organization. Those areas require additional authoritative sourcing before they can be added to the dossier.

• 2017

  Exchange delisting

  [1]Pharmstandarden.wikipedia.org

  Pharmstandard is delisted from the London and Moscow stock exchanges.

• 2013

  Bever Pharmaceutical acquisition plan

  [1]Pharmstandarden.wikipedia.org

  The company announces plans to acquire ingredient supplier Bever Pharmaceutical; its shares reportedly decline by 25% after the announcement.

• 2008

  Abramovich stake ends

  [1]Pharmstandarden.wikipedia.org

  Roman Abramovich is reported to have held a 17% stake until March 2008.

• 2007

  Initial public offering

  [1]Pharmstandarden.wikipedia.org

  Pharmstandard raises approximately US$880 million in an initial public offering, with an indicated valuation of about US$2.2 billion.

• 2003

  Pharmstandard is established

  [1]Pharmstandarden.wikipedia.org

  The company is formed through a merger and begins operating as a Russian pharmaceutical manufacturer.

A large Russian pharmaceutical manufacturer and exporter with a broad generic and proprietary medicine portfolio.

• Antiviral medicine

  Arbidol

  Arbidol is an antiviral medicine associated with Pharmstandard and is one of the company's best-known branded offerings. It forms part of the company's infectious-disease and antiviral portfolio. The supplied sources do not provide sufficient detail to document its launch date, current formulation range, regulatory status in individual markets, or present commercial importance.

• Prescription medicines

  Prescription medicine portfolio

  Pharmstandard produces a broad range of prescription medicines across therapeutic areas identified in the reference material, including diabetes, growth hormone deficiency, cardiovascular disease, gastroenterology, neurology, infectious diseases, and oncology. The portfolio includes both generic and proprietary products, but the supplied sources do not enumerate every product or identify current sales status for individual medicines.

• Over-the-counter medicines

  Over-the-counter medicine portfolio

  The company also manufactures non-prescription medicines for consumer use. These products sit alongside its prescription portfolio and contribute to Pharmstandard's broad domestic and export-market offering. The available material does not specify the complete brand list, individual launch dates, or current status of particular over-the-counter lines.

• 2017

  Withdrawal from London and Moscow stock exchangesStrategy

  Background

  After an earlier period as a publicly traded pharmaceutical company, Pharmstandard ended its exchange-listed status.

  Action taken

  The company was delisted from the London and Moscow stock exchanges.

  Aftermath

  Pharmstandard no longer had listings on those exchanges. The supplied sources do not explain the reasons for the delisting or identify its subsequent ownership structure.

  Source

• 2013

  Plan to acquire Bever PharmaceuticalM&A

  Background

  Pharmstandard announced a plan to purchase Bever Pharmaceutical, an ingredient supplier, as part of a potential expansion into the pharmaceutical supply chain.

  Action taken

  The company publicly announced the proposed acquisition. The supplied reference does not confirm whether the transaction was completed.

  Aftermath

  Pharmstandard's shares reportedly fell by 25% following the announcement. No further outcome is established by the supplied sources.

  Reported share-price change. -25% (2013, following the acquisition announcement)

  Source

1. 1Pharmstandarden.wikipedia.org
2. 2Pharmstandard official websitepharmstd.ru